1Durrington PN, Hunt I, Ishola M, et al. Serum apolipopro- teins AL and lipoproteins in middle-aged men with and with- out previous myocardial infraction. Br Heart J, 1986,56 .. 206- 212.
2Talmud PJ, Hawe E, Miller GJ, et al. Non-fasting apoli-poprotein B and triglyceride levels as a useful predictor coro- nary heart diease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol,2002,22 : 1981-1923.
3van Lennep JE,Westerveld HT,van Lennep HW, et al. Apo- lipoprotein concentration during treatment and recurrent cor- onary artery diease events. Arterioscler Thromb Vasc Biol, 2000,20 : 2408-2413.
4Sniderman AD, Jungner I, Holme I, et al. Errors that re- sult from the TC/HDL C ratio rather than the apoB/ApoA1 ratio to identify the lipoprotein--related risk of vascular dis- ease. J Intern Med,2006,259: 455-461.
5Yusuf S, Hawken S, unpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet,2004,364: 937-952.
6Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholester- ol, apolipoproteins A1 and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular dis- ease in women. JAMA,2005,294: 326-333.
7Walldius G, Jungner I. The apoB/ApoA1 ratio: a strong, new risk factor for cardiovascular disease and a target for lip- id-lowering therapy-a review of the evidence. J Intern Med, 2006,259: 493-519.
8Marcovina S, Packard J. Measurement and meaning of apoli- poprotein AI and apolipoprotein B plasma levels. J Intern Med,2006, 259: 437-446.
9McNamara JR, Conh JS, Wilson PWF. Calculated values of low-density lipoprotein in the assessment of lipid abnormali- ties and coronary disease risk. Clin Chem, 1990,36:36-42.
10Esteban-Saldn M, Guim6n-Berdesi A, de la Viuda-Unzueta JM. Analytical and clinical evaluation of two homogeneous assays for LDL-eholesterol in hyperlipidemic patients. Clin Chem,2000,46: 1121-1131.
4Ogasawara K,Mashiba S,Hashimoto H,et al.Low-densitylipoprotein(LDL),which includes apolipoprotein A-I(apoA I-LDL)as a novel marker of coronary artery disease.Clin ChimActa,2008,397(1/2):42-47.
5Agoston-Coldea L,Zdrenghea D,Pop D,et al.ApolipoproteinsA-I and B-markers in coronary risk evaluation.Rom J InternMed,2007,45(3):251-258.
6Pajukanta P,Porkka KV.Genetics of familial combined hyperlipidemia.Curr Atheroscler Rep,1999,1(1):79-86.
7Humphries SE,Needly RD,Whittall RA,et al.Healthy individuals carrying the PCSK9p.R46Lvariant and familial hypercholesterolemia patients carrying PCSK9p.D374Yexhibit lower plasma concentrations of PCSK9.Clin Chem,2009,55:2153-2161.
8Bedi M,Niesen D,Loper D.Inhibition of squalene synthase upregulates PCSK9expression in rat liver.Arch Biochem Biophys,2008,470(2):116-119.
9Humphries SE,Whittal RA,Hubbart CS,et al.Genetic causes of familial hypercholesterolaemia in patients in the UK:relation to plasma lipid levels and coronary heart disease risk.J Med Genet,2006,43:943-949.
